Published in Brain on February 04, 2011
CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation (2011) 1.27
Development of amyloid burden in African Green monkeys. Neurobiol Aging (2013) 0.82
Heavy metals in locus ceruleus and motor neurons in motor neuron disease. Acta Neuropathol Commun (2013) 0.81
Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. Br J Pharmacol (2014) 0.78
Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications. Curr Neuropharmacol (2014) 0.78
Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediators. J Neuroinflammation (2013) 0.77
Sympathetic cardiovascular and sudomotor functions are frequently affected in early multiple sclerosis. Clin Auton Res (2016) 0.77
Ozone Therapy in Ethidium Bromide-Induced Demyelination in Rats: Possible Protective Effect. Cell Mol Neurobiol (2015) 0.75
Multiple sclerosis: Noradrenaline deficits suggest novel MS treatments. Nat Rev Neurol (2011) 0.75
Down but Not Out: The Consequences of Pretangle Tau in the Locus Coeruleus. Neural Plast (2017) 0.75
The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci (2009) 3.67
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol (2003) 3.57
The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity. Immunity (2008) 1.73
Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry (1979) 1.71
Disease-specific patterns of locus coeruleus cell loss. Ann Neurol (1992) 1.64
Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev (2004) 1.63
Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol (2007) 1.57
Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology (1999) 1.52
Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci (2006) 1.46
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J Neurosci (1992) 1.37
Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging (2002) 1.35
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol (2008) 1.34
Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res (1983) 1.29
Th17 cells in autoimmune demyelinating disease. Semin Immunopathol (2010) 1.27
Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res (2008) 1.23
The pathology of the human locus ceruleus. Clin Neuropathol (1983) 1.20
The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology (2009) 1.20
Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem (1997) 1.17
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging (2006) 1.11
Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat (2007) 1.11
Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets (2007) 1.11
Abnormal development of the locus coeruleus in Ear2(Nr2f6)-deficient mice impairs the functionality of the forebrain clock and affects nociception. Genes Dev (2005) 1.10
Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol (1983) 1.10
The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing Dev (1983) 1.06
Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord (1987) 1.06
Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect (1993) 1.06
Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain (1995) 1.05
Functional evidence that BDNF is an anterograde neuronal trophic factor in the CNS. J Neurosci (1998) 1.05
Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol (2002) 1.00
Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc Natl Acad Sci U S A (1988) 1.00
The human locus coeruleus: computer reconstruction of cellular distribution. J Neurosci (1988) 0.99
The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol (2006) 0.99
Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology (1997) 0.99
Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J Neurochem (1993) 0.99
Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem (2007) 0.98
The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J Comp Neurol (2005) 0.98
Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J Neurochem (2001) 0.98
Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int (2010) 0.97
The projections of locus coeruleus neurons to the spinal cord. Prog Brain Res (1991) 0.96
Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res (1991) 0.95
Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain (2003) 0.94
Norepinephrine protects cortical neurons against microglial-induced cell death. J Neurosci Res (2005) 0.94
Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol (2009) 0.93
Alzheimer's disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience (1987) 0.92
Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J Neuroimmunol (2010) 0.91
Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Physiol (1998) 0.89
Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol (2003) 0.88
Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol (2008) 0.88
A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.88
The protective influence of the locus ceruleus on the blood-brain barrier. Ann Neurol (1984) 0.86
Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development (2003) 0.86
beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann Neurol (1992) 0.85
Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid Redox Signal (2006) 0.84
Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav Immun (2010) 0.84
Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid Redox Signal (2006) 0.83
Second messenger systems in the regulation of cytokines and adhesion molecules in the central nervous system. Brain Behav Immun (1995) 0.81
Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J Neuroinflammation (2007) 0.81
Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain. Eur J Neurosci (2006) 0.81
Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol (1993) 0.81
The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Mult Scler (2006) 0.80
Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem Int (2007) 0.80
An immunocytochemical study of normal and abnormal human cerebrospinal fluid with monoclonal antibodies to glial fibrillary acidic protein. Acta Cytol (1986) 0.80
MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport (2001) 0.79
Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J Neurochem (2008) 0.79
Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. Neurosci Lett (2009) 0.79
Developmental regulation of spinal motoneurons by monoaminergic nerve fibers. J Peripher Nerv Syst (1997) 0.78
Ultrastructural aspects of the coeruleo-spinal projection. Prog Brain Res (1991) 0.78
Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J Neurochem (1983) 0.77
Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord. J Neurochem (1986) 0.77
[Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis]. Biull Eksp Biol Med (1975) 0.77
Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med (2003) 3.87
Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. Crit Care Med (2009) 3.56
Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. Reg Anesth Pain Med (2006) 2.74
Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. Anesthesiology (2009) 2.11
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem (2007) 1.61
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.29
Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology (2008) 1.28
Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci (2009) 1.22
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro (2011) 1.19
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem (2002) 1.18
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation (2008) 1.12
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging (2006) 1.11
The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol (2002) 1.10
Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J Neurochem (2005) 1.10
The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation (2011) 1.05
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem (2006) 1.04
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol (2003) 1.04
Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammation (2004) 1.03
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging (2011) 1.03
mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia (2012) 1.02
Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation (2004) 1.00
A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2009) 0.99
Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem (2007) 0.98
Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation (2007) 0.95
Norepinephrine protects cortical neurons against microglial-induced cell death. J Neurosci Res (2005) 0.94
Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol (2009) 0.93
The role of the glia limitans in ADP-induced pial arteriolar relaxation in intact and ovariectomized female rats. Am J Physiol Heart Circ Physiol (2004) 0.92
Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res (2004) 0.92
Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain. PLoS One (2010) 0.91
Epinephrine induces rapid deterioration in pulmonary oxygen exchange in intact, anesthetized rats: a flow and pulmonary capillary pressure-dependent phenomenon. Anesthesiology (2012) 0.91
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol (2009) 0.91
Modulation of inducible nitric oxide synthase expression by sumoylation. J Neuroinflammation (2009) 0.91
Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem (2003) 0.90
Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport (2002) 0.89
Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol (2003) 0.88
Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology (2005) 0.86
15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway. J Neurochem (2006) 0.86
Norepinephrine increases I kappa B alpha expression in astrocytes. J Biol Chem (2002) 0.85
Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid Redox Signal (2006) 0.84
Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett (2010) 0.84
Regulation of MCP-1 production in brain by stress and noradrenaline-modulating drugs. J Neurochem (2010) 0.83
Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised. J Neuroinflammation (2004) 0.83
Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol (2011) 0.83
Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid Redox Signal (2006) 0.83
An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding. PLoS One (2011) 0.82
Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J Neurochem (2003) 0.82
Development of amyloid burden in African Green monkeys. Neurobiol Aging (2013) 0.82
Intraosseous lipid emulsion: an effective alternative to IV delivery in emergency situations. Crit Care Med (2014) 0.81
Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes. Neurosci Lett (2007) 0.81
Degeneration of noradrenergic fibres from the locus coeruleus causes tight-junction disorganisation in the rat brain. Eur J Neurosci (2006) 0.81
Adding bupivacaine to high-potassium cardioplegia improves function and reduces cellular damage of rat isolated hearts after prolonged, cold storage. Anesthesiology (2006) 0.80
Brodifacoum induces early hemoglobinuria and late hematuria in rats: novel rapid biomarkers of poisoning. Am J Nephrol (2015) 0.80
Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. J Neurosci Res (2002) 0.79
Pioglitazone attenuates acute cocaine toxicity in rat isolated heart: potential protection by metabolic modulation. Anesthesiology (2011) 0.78
Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. ASN Neuro (2010) 0.78
Dimethyl fumarate regulates histone deacetylase expression in astrocytes. J Neuroimmunol (2013) 0.77
Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease. Adv Pharmacol (2012) 0.77
The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE. J Neuroimmunol (2012) 0.77
The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus. J Neurochem (2012) 0.77
Beneficial effects of blueberries in experimental autoimmune encephalomyelitis. J Agric Food Chem (2012) 0.76
PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors. PPAR Res (2008) 0.76
Sevoflurane reduces clinical disease in a mouse model of multiple sclerosis. J Neuroinflammation (2012) 0.76
IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis. J Neuroimmunol (2013) 0.75
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology (2008) 0.75
Effects of peptide fraction and counter ion on the development of clinical signs in experimental autoimmune encephalomyelitis. J Neurochem (2014) 0.75
NO and glial cell biology. Antioxid Redox Signal (2006) 0.75